AFP産生胃癌におけるHER2の時空間的異質性:難治性症例における分子標的療法による長期生存のナビゲート
Yanwen Diao1, Haobo Yin1, Xin Sun1
1Medical Oncology Department of Gastrointestinal Tumors, Liaoning Cancer Hospital and Institute, Liaoning Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Shenyang, China.
Abstract:
Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare, aggressive subtype with poor prognosis. We report a metastatic AFPGC case showing spatiotemporal human epidermal growth factor receptor 2 (HER2) heterogeneity. Following progression on first-line FLOT chemotherapy, the 65-year-old male received second-line apatinib plus programmed death-1 (PD-1) inhibitor. At progression (27 months), a lymph node biopsy revealed HER2 conversion from 1+ to 3 +. Third-line anti-HER2 antibody-drug conjugate (ADC) DP303c rapidly achieved partial response with normalized AFP. Despite treatment discontinuation due to neurotoxicity after 5 cycles, response persisted. Overall survival reached 79 months. This case highlights: 1) efficacy of anti-angiogenic and immunotherapy in AFPGC; 2) necessity of re-biopsy for detecting HER2 heterogeneity; and 3) potent activity of ADCs against HER2-converted metastases, enabling remarkable survival through sequential precision therapy.
関連する概念動画
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
08:42Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
06:36Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
07:03Dynamic Navigation in Endodontics: Guided Access Cavity Preparation by Means of a Miniaturized Navigation System
08:26Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages


